Caris Precision Oncology Alliance Welcomes VCU Massey Cancer Center | Biden News


Massey joins Caris’ extensive network of leading cancer institutions committed to leveraging clinical data to advance patient care and outcomes

IRVING, Texas, Oct. 25, 2022 /PRNewswire/ — Caris Life Sciences®(Caris), a leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, today announced that Virginia Commonwealth University (VCU) Massey Cancer Center (Massey) has joined the Caris’ Precision Oncology Alliance™ (POA). ). POA is a growing network of leading cancer centers around the world collaborating to advance precision oncology and biomarker-based research. POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve clinical outcomes for cancer patients.

Caris Life Sciences Logo (PRNewsfoto/Caris Life Sciences)

Founded in 1974, Massey is the only cancer center in the Richmond metropolitan area and the first of only two in the state to be designated by the National Cancer Institute, placing it among the top four percent of cancer centers in the nation. Massey scientists and physicians collaborate to conduct laboratory, translational, clinical and population science research to find new and better ways to prevent, diagnose, treat, and control cancer. Their research members were faculty from 39 departments across nine schools and colleges at VCU.

“Massey is delighted to join the Caris Precision Oncology Alliance,” said Robert A. Winn, MD, Director and Lipman Chair in Oncology at VCU Massey Cancer Center. “Precision medicine is a game changer in the scientific world. POA Caris provides Massey researchers with the opportunity to join a growing number of academic cancer centers and collaboratively study patient outcomes based on unique molecular profiles.”

“We are pleased to welcome VCU Massey Cancer Center to the growing Caris Precision Oncology Alliance network and look forward to driving this research collaboration,” said Chadi Nabhan, MD, MBA, FACP, Chair of the Caris Precision Oncology Alliance. “Our shared interest in precision oncology and a patient-centred approach will allow VCU and POA to work together towards a common goal of improving outcomes for all patients with cancer.”

The Caris Precision Oncology Alliance includes 73 cancer centers and academic institutions. These institutions have early access to the extensive database and artificial intelligence platform within Caris for setting evidence-based standards for cancer profiling and advanced research in cancer precision medicine. By leveraging the comprehensive genomic, transcriptomics, and proteomics profiles available through the Caris molecular profiling, Caris seeks to provide these networks with the ability to prioritize therapeutic options and determine which clinical trial opportunities may benefit their patients.

“What excites me is the potential,” says Winn. “The potential to see results based on a unique molecular profile, and the potential since then to tie it together with the ZNA – that is, your zip code and association environment in the context of a study via the Caris POA Health Disparity Council. What impact does a person’s environment have on their biology? Well, that’s is personalized medicine.”

POA members can also integrate with the growing portfolio of biomarker targeted trials sponsored by biopharma. Additionally, as a POA member, institutions have access to Caris CODEai™, the industry’s most comprehensive data solution with cancer care information and clinical outcome data for more than 275,000 patients covering more than 1 million data points per patient.

About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare and improve patient outcomes. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale clinical-genomic database and cognitive computations needed to analyze and uncover the molecular complexities of disease. This information provides an unrivaled resource and an ideal path forward for conducting basic and fundamental research to accelerate discovery for detection, diagnosis, monitoring, selection of therapies and development of drugs to improve the human condition.

With a primary focus on cancer, Caris’ market-leading range of molecular profiling offers assesses DNA, RNA and protein to reveal molecular blueprints that help patients, doctors and researchers better detect, diagnose and treat patients. Caris’ latest advancement is a blood-based circulating nucleic acid sequencing (cNAS) assay that combines comprehensive molecular analysis (Whole Exome and Whole Transcriptome sequencing of blood) and serial monitoring – making it the most powerful liquid biopsy assay ever developed.

Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Denver, Tokyo, Japan and Basel, Switzerland. Caris provides services throughout the US, Europe, Asia and other international markets. To learn more, please visit or follow us on Twitter (@CarisLS).

About VCU Massey Cancer Center
VCU Massey Cancer Center is working towards a cancer-free future – one discovery, one therapy that works, and one life saved at a time. Among the top 4 percent of cancer centers in the nation designated by the National Cancer Institute to lead and shape America’s cancer research efforts, Massey is dedicated to saving and improving lives by discovering, developing, delivering, and teaching effective ways to prevent, detect and treat cancer. and make that progress equally available to everyone. Massey is leading the nation in building a 21st century equity model for cancer research and care, where the community informs and partners with Massey in its research to address the cancer burden and the gaps served by cancer centers. Massey conducts cancer research spanning basic, translational, clinical and population sciences; offering state-of-the-art cancer therapies and clinical trials, including a network that brings trials to communities across the state; provide oncology education, teaching and training; and promote cancer prevention. At Massey, subspecialty oncologists collaborate in multidisciplinary teams to provide award-winning comprehensive cancer care in locations throughout Virginia. Visit Massey online at or call 877-4-MASSEY for more information.

Caris Life Sciences Media Contact:
Lisa Burger

Massey Cancer Center VCU Media Contact:
Annie Harris

cision View original content to download multimedia:

SOURCE Caris Life Sciences


Source link